FDA Approves Unknown Drug — SANDOZ

Sandoz has received FDA approval for a line extension of its high-titer Emgality biosimilar, a 40 mg/administration formulation set to enter the Alpha sector of the migraine market. This expanded dosage range is expected to diversify Sandoz’s top-line revenue streams in the migraine segment, directly challenging tricyclic antidepressant business losses and intensifying competition within the 120 mg dosage class.